Navigation Links
Cancer Antibodies: Drug Target Atlas and Competitive Outlook
Date:11/15/2012

NEW YORK, Nov. 15, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Cancer Antibodies: Drug Target Atlas and Competitive Outlook

http://www.reportlinker.com/p01033839/Cancer-Antibodies-Drug-Target-Atlas-and-Competitive-Outlook.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Personalized medicine is very much about fitting target profiles of drugs towards disease mechanism(s). This report is a new and unique way of stratifying and analyzing the global antibody pipeline in cancer towards personalized medicine and presents actionable analysis which allows you to discover:

* Where the competition is; Which targets, tumor types and companies are setting the path?

* How much R&D effort has gone towards different targets and what is known about the target?

* Indication expansion opportunities

* Drug repositioning opportunities

* Which pathways are targeted, by what and how?

* What is truly new and unique in the antibody pipeline in cancer?

* How new and unique your target strategy really is

* Locate the right drugs to benchmark against and see were others may have succeeded or failed before you.

BioSeeker builds its analysis on a comprehensive base of 572 antibody drugs in cancer from within the portfolio of 205 companies world-wide, from Ceased to Marketed. We have identified 270 drug targets, which we have organized into 279 drug target strategies, and assessed them by four levels:

1. Individual Target: Shows you how individual targets tie into different target strategies and their subsequent R&D progress.

2. Developmental Stage: Shows you the progress and maturation of different target strategies. Identifies which target strategies are new and unique from one developmental stage to the next.

3. Indication: Shows the distribution and deployment of target strategies by cancer indications. The competitive level in each cancer indication is assessed.

4. Company: Provides a cross-examination of each company's entire pipeline on the basis of its defined drug target strategies, including a Competitive Fall-Out analysis and a corporate pipeline ranking based on 15 parameters.

Our Analysis includes:

* Head-to-head target competing analysis

* Significant drug target overlap analysis

* Cross-sectional R&D profiling of individual drug targets.

* Cross-over analysis of target strategies among different tumor types.

* Competitive Fall-Out analysis of the entire company pipeline: Answering three core questions about each company's pipeline: -Where are we?-Where is our general and specific competition?-What is the level of competition where we want to be?

* 15 parameter deep corporate pipeline ranking, including both internal and external pipeline factors.

The report serves as an external commercial advocate for your company's interest in the antibody pipeline in cancer by: * Better identifying benchmarking peers

* Providing rationale for in/out licensing decisions of drug candidates

* Performing proper drug due diligence

* Strategies for commercial planning

* Guiding Research & Development efforts

1 Executive Summary 32 About Cancer Highlights™ 52.1 Cancer Focus Areas 52.2 Subscribe Today and Start Saving 62.2.1 Type of License 62.3 Additional Information 62.4 BioSeeker Group's Oncology Team 63 Methodology 73.1 Cancer Highlights'™ Five Pillar Drug Assessment 74 Table of Contents 94.1 List of Figures 234.2 List of Tables 235 Introduction 355.1 The Scope of this Report 355.2 Definitions 385.3 Abbreviations 386 Consider the Therapeutic Target Among Antibody Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment 396.1 Drug Repositioning in Oncology 396.2 Introduction to Targets of Antibody Drugs in Cancer 406.2.1 Antigen Binding Targets 496.2.2 ATPase Activity Targets 516.2.3 Auxiliary Transport Protein Activity Targets 536.2.4 B Cell Receptor Activity Targets 566.2.5 Binding Targets 576.2.6 Carboxypeptidase Activity Targets 586.2.7 Catalytic Activity Targets 606.2.8 Cell Adhesion Molecule Activity Targets 646.2.9 Chaperone Activity Targets 886.2.10 Chemokine Activity Targets 916.2.11 Cofactor Binding Targets 956.2.12 Complement Activity Targets 976.2.13 Cysteine-type Peptidase Activity Targets 1016.2.14 Cytokine Activity Targets 1036.2.15 Defense/Immunity Protein Activity Targets 1106.2.16 DNA Topoisomerase Activity Targets 1116.2.17 Extracellular Ligand-gated Ion Channel Activity Targets 1146.2.18 Extracellular Matrix Structural Constituent Targets 1156.2.19 G-protein Coupled Receptor Activity Targets 1216.2.20 Growth Factor Activity Targets 1346.2.21 Guanylate Cyclase Activity Targets 1496.2.22 Hormone Activity Targets 1506.2.23 Hydrolase Activity Targets 1516.2.24 Intracellular Ligand-gated Ion Channel Activity Targets 1536.2.25 Kinase Binding Targets 1546.2.26 Metallopeptidase Activity Targets 1556.2.27 MHC Class I Receptor Activity Targets 1596.2.28 Molecular Function Unknown Targets 1606.2.29 Oxidoreductase Activity Targets 1896.2.30 Peptidase Activity Targets 1906.2.31 Peptide Hormone Targets 1926.2.32 Protease Inhibitor Activity Targets 1946.2.33 Protein Binding Targets 1966.2.34 Protein Serine/Threonine Kinase Activity Targets 1976.2.35 Receptor Activity Targets 2016.2.36 Receptor Binding Targets 2696.2.37 Receptor Signaling Complex Scaffold Activity Targets 2826.2.38 Receptor Signaling Protein Serine/Threonine Kinase Activity Targets 2846.2.39 Receptor Signaling Protein Tyrosine Phosphatase Activity Targets 2866.2.40 RNA-directed DNA Polymerase Activity Targets 2876.2.41 Serine-type Peptidase Activity Targets 2886.2.42 Structural Constituent of Cytoskeleton Targets 2916.2.43 Structural Molecule Activity Targets 2936.2.44 T Cell Receptor Activity Targets 2946.2.45 Transcription Factor Activity Targets 2966.2.46 Transcription Regulator Activity Targets 3016.2.47 Translation Regulator Activity Targets 3046.2.48 Transmembrane Receptor Activity Targets 3056.2.49 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets 3146.2.50 Transporter Activity Targets 3486.2.51 Other Targets 3526.3 Mutation Profiles of Antibody Drug Targets in Oncology 3566.3.1 Targets of Antibody Drugs in Cancer Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer 3566.4 Antibody Therapeutics is Stimulated by Available Structure Data on Targets 3646.5 Target-Target Interactions among Identified Targets of Antibody Drugs in Cancer 3686.6 Protein Expression Levels of Identified Targets of Antibody Drugs in Cancer 3726.7 The Drug-Target Competitive Landscape 3756.8 Pathway Assessment of Antibody Drugs in Cancer 3816.8.1 Tools for Analysis of Cancer Pathways 3826.8.2 Pathway Assessment 3837 Emerging Drug Candidates to Established Ones: Drug Target Strategies of Antibody Drugs in Cancer by their Highest Stage of Development 4237.1 Pre-registrered and Marketed: New and Unique Drug Target Strategies of Antibody Drugs in Cancer 4267.2 Phase III Clinical Development: New and Unique Drug Target Strategies of Antibody Drugs in Cancer 4287.3 Phase II Clinical Development: New and Unique Drug Target Strategies of Antibody Drugs in Cancer 4307.4 Phase I Clinical Development: New and Unique Drug Target Strategies of Antibody Drugs in Cancer 4357.5 Preclinical Development: New and Unique Drug Target Strategies of Antibody Drugs in Cancer 4427.6 Drug Target Strategies of Suspended or Terminated Antibody Drugs in Cancer 4517.7 Target Strategy Development Profiles of Antibody Drugs in Cancer 4567.7.1 Marketed 4627.7.2 Phase III 4837.7.3 Phase II 4987.7.4 Phase I 5687.7.5 Preclinical 6167.7.6 Suspended 6967.7.7 Ceased 6977.8 The Competition Through Close Mechanistic Approximation of Antibody Drugs in Cancer 7688 Selecting Indication for Antibody Drugs in Oncology 7778.1 Acute Lymphocytic Leukemia 7808.2 Acute Myelogenous Leukemia 7828.3 B-cell Lymphoma 7848.4 Basal Cell Cancer 7868.5 Biliary Cancer 7878.6 Bladder Cancer 7888.7 Bone Cancer 7908.8 Brain Cancer 7938.9 Breast Cancer 7958.10 Cancer (general) 7998.11 Carcinoid Tumors 8008.12 Cervical Cancer 8018.13 Chronic Lymphocytic Leukemia 8038.14 Chronic Myelogenous Leukemia 8068.15 Chronic Myelomonocytic Leukemia 8078.16 CNS Cancer 8088.17 Colorectal Cancer 8098.18 Endometrial Cancer 8138.19 Esophageal Cancer 8148.20 Ewing's Sarcoma 8158.21 Fallopian Tube Cancer 8168.22 Gastrointestinal Cancer (general) 8178.23 Gastrointestinal Stomach Cancer 8198.24 Gastrointestinal Stromal Cancer 8218.25 Genitourinary Cancer 8228.26 Glioma 8238.27 Hairy Cell Leukemia 8248.28 Head and Neck Cancer 8258.29 Hematological Cancer (general) 8278.30 Hodgkin's Lymphoma 8288.31 Leiomyo Sarcoma 8308.32 Leukemia (general) 8318.33 Liver Cancer 8338.34 Lung Cancer (general) 8358.35 Lymphoma (general) 8378.36 Malignant ascites 8388.37 Melanoma 8398.38 Merkel Cell Carcinoma 8428.39 Mesothelioma 8438.40 Myelodysplastic Syndrome 8448.41 Myeloma 8468.42 Nasopharyngeal Cancer 8498.43 Neuroblastoma 8508.44 Neuroectodermal Sarcoma 8518.45 Neuroendocrine Cancer (general) 8528.46 non-Hodgkin's Lymphoma 8538.47 Non-Small Cell Lung Cancer 8578.48 Oesophageal Cancer 8608.49 Oral Cancer 8638.50 Osteo Sarcoma 8648.51 Ovarian Cancer 8658.52 Pancreatic Cancer 8688.53 Peritoneal Cancer 8718.54 Pituitary Adenoma 8738.55 Prostate Cancer 8748.56 Renal Cancer 8778.57 Rhabdomyo Sarcoma 8798.58 Sarcoma (general) 8808.59 Skin Appendage Cancer 8818.60 Skin Cancer (general) 8828.61 Small Cell Lung Cancer 8838.62 Soft Tissue Sarcoma 8858.63 Solid Tumor 8868.64 Squamous Cell Cancer 8908.65 Synovial Sarcoma 8928.66 T-cell Lymphoma 8938.67 Testicular Cancer 8948.68 Thymoma Cancer 8958.69 Thyroid Cancer 8968.70 Unspecified Cancer Type 8988.71 Vaccine adjunct 9058.72 Waldenstrom's hypergammaglobulinemia 9069 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Antibody Drug Pipeline by Investigator 9089.1 Changes in the Competitive Landscape: M&A, Bankruptcy and Name Change 9139.2 Company Facts and Ranking 9159.3 Competitive Fall-Out Assessment 9229.4 A&G Pharmaceutical 9259.5 Abbott 9299.6 Abcam 9389.7 Abiogen 9469.8 Ablynx 9559.9 AC Immune 9609.10 Acceleron Pharma 9649.11 Access 9689.12 Actinium Pharmaceuticals 9749.13 Active Biotech 9809.14 Adherex 9849.15 Affibody 9889.16 Affimed Therapeutics 9959.17 Affitech 10069.18 AGY Therapeutics 10139.19 Aida Pharmaceuticals 10179.20 Alder Biopharmaceuticals 10239.21 Alethia Biotherapeutics 10309.22 Alexion 10349.23 Algeta 10389.24 ALSP 10469.25 Altor BioScience 10539.26 Amgen 10579.27 Amorfix Life Sciences 10869.28 Antisoma 10919.29 Aphios 10979.30 Apricus Biosciences 11039.31 Arana Therapeutics 11119.32 Arca biopharma 11159.33 Areva 11199.34 arGEN-X 11269.35 Astellas 11319.36 1AstraZeneca 11359.37 AVEO 11569.38 Bayer 11679.39 Berkeley Lab 11739.40 Biocon 11779.41 Biogen Idec 11819.42 BioInvent 11959.43 Biolex 11999.44 BioLineRx 12069.45 Biosceptre 12109.46 Biotecnol 12149.47 Biotest 12229.48 Boehringer Ingelheim 12269.49 Bristol-Myers Squibb 12309.50 BTG 12539.51 Cancer Innovations 12589.52 Cancer Research Technology 12639.53 Celldex Therapeutics 12809.54 Celltrion 12879.55 Celtic Pharma 12979.56 Center of Molecular Immunology 13029.57 Centrose 13109.58 CG Therapeutics 13169.59 Circadian Technologies 13209.60 CSL 13259.61 CuraGen 13299.62 CureTech 13339.63 Customized Therapeutics 13399.64 CytImmune Sciences 13479.65 Daiichi Sankyo 13519.66 Dendreon 13589.67 DiaMedica 13639.68 Dompe 13679.69 Dr Reddy's 13729.70 Dyax 13799.71 Eisai 13869.72 Elan 13939.73 Eli Lilly 13979.74 Emergent BioSolutions 14249.75 Ergon Pharmaceuticals 14289.76 EUSA Pharma 14329.77 Expression Drug Designs 14379.78 Fabrus 14419.79 Faron Pharmaceuticals 14569.80 Favrille 14609.81 Femta Pharmaceuticals 14679.82 FibroGen 14729.83 Five Prime Therapeutics 14769.84 Fusion Antibodies 14809.85 Galaxy Biotech 14849.86 GammaCan 14889.87 Ganymed Pharmaceuticals 14949.88 Gene Techno Science 14989.89 Genencor 15029.90 Genentech 15079.91 Genmab 15179.92 Genomic Systems 15389.93 GenPat77 15429.94 Gilead Sciences 15469.95 GlaxoSmithKline 15509.96 Gliknik 15589.97 Glycotope 15689.98 Green Cross 15789.99 Hawthorn Pharmaceuticals 15859.100 Hoffmann-La Roche 15899.101 Human Genome Sciences 16299.102 IDM Pharma 16379.103 ImClone Systems 16469.104 IMED 16539.105 Immune Pharmaceuticals 16579.106 ImmunoCellular Therapeutics 16619.107 ImmunoGen 16659.108 Immunomedics 16809.109 Immutep 17079.110 Innate Pharma 17119.111 InNexus Biotechnology 17179.112 Intracel 17319.113 ISA Pharmaceuticals 17389.114 ISU ABXIS 17439.115 Johnson & Johnson 17509.116 Kaketsuken 17589.117 KaloBios 17629.118 Kirin Pharma 17669.119 Kissei 17739.120 Kyowa Hakko Kirin 17809.121 Kyto Biopharma 17879.122 LFB Biotechnologies 17919.123 LG Life Sciences 18059.124 MacroGenics 18129.125 MAT Biopharma 18209.126 Medarex 18279.127 MediGene 18349.128 MedImmune 18419.129 Menarini 18469.130 Merck & Co 18519.131 Merck KGaA 18579.132 Merrimack 18709.133 Micromet 18769.134 Mitsubishi Tanabe Pharma 18819.135 Mycenax 18859.136 Neovacs 18899.137 Neuren 18959.138 NIH 18999.139 NKT Therapeutics 19059.140 Non-industrial Sources 19099.141 Northwest Biotherapeutics 19179.142 Novartis 19229.143 OncoMed 19369.144 OncoTherapy Science 19429.145 Oncothyreon 19469.146 Onyvax 19519.147 Oxford BioMedica 19569.148 Paladin Labs 19619.149 Panacea 19689.150 PanGenetics 19749.151 Patrys 19799.152 Pepscan Therapeutics 19869.153 Peregrine Pharmaceuticals 19919.154 Perseus Proteomics 19989.155 Pfizer 20039.156 PharmAbcine 20229.157 Philogen 20459.158 Pierre Fabre 20519.159 Prima Biomed 20609.160 PROBIOMED 20659.161 ProCell Therapeutics 20729.162 Prochon Biotech 20769.163 Progenics Pharmaceuticals 20829.164 Ramot 20879.165 Recepta biopharma 20919.166 Receptor BioLogix 20959.167 Regeneron 21019.168 Sanofi 21109.169 SBI Biotech 21169.170 Scancell 21219.171 Seattle Genetics 21259.172 Shanghai CP Guojian 21369.173 Shenogen 21469.174 Stainwei Biotech 21509.175 Sunol Molecular 21569.176 SuppreMol 21619.177 Switch Pharma 21669.178 Symphogen 21709.179 Synageva BioPharma 21789.180 SynerGene Therapeutics 21889.181 Tactic Pharma 21929.182 Takeda 21969.183 Tamir Biotechnology 22029.184 Targa Therapeutics 22079.185 TeGenero 22159.186 Teva 22199.187 ThromboGenics 22269.188 Titan Pharmaceuticals 22319.189 Tolerx 22379.190 Tracon Pharmaceuticals 22429.191 Transgene 22479.192 Trillium Therapeutics 22529.193 Trion Pharma 22569.194 UCB 22649.195 United Therapeutics 22709.196 Vaccinex 22749.197 VasGene Therapeutics 22839.198 Viragen 22879.199 Viventia Biotech 22939.200 Wakunaga 22979.201 Wilex 23039.202 XBiotech 23079.203 Xencor 23129.204 Xerion 23319.205 Xoma 23379.206 Y's Therapeutics 23439.207 YM BioSciences 23479.208 Zenotech 235410 Disclaimer 2361

1.1 List of Figures

Figure 1: Visualization of Target-Target Interactions among Targets of Antibody Drugs in Cancer 371

Figure 2: The Drug-Target Competitive Landscape of Antibody Drugs in Cancer - Large Cluster 376

Figure 3: The Drug-Target Competitive Landscape Antibody Drugs in Cancer - Smaller Clusters 1(2) 377

Figure 4: The Drug-Target Competitive Landscape Antibody Drugs in Cancer - Smaller Clusters 2(2) 378

Figure 5: Head-to-Head Targeting Competitive Landscape of Antibody Drugs in Cancer - 1 (2) 379

Figure 6: Head-to-Head Targeting Competitive Landscape of Antibody Drugs in Cancer - 2 (2) 380

Figure 7: Number of Companies per Ranking Level 917

1.2 List of Tables

Table 1: Cancer Highlights'™ Five Pillar Drug Assessment 7Table 2: Breakdown of the Included Antibody Drug Pipeline in Oncology by Stage of Development 35Table 3: Head to Head Target Competition among Antibody Drugs 35Table 4: Overview of Drug Target Strategy Themes 40Table 5: Ceased Targets of Antibody Drugs in Cancer 41Table 6: Official Gene Symbol to Target Profle 43Table 7: Mutation Frequencies of Antibody Drug Targets 357Table 8: Identity of Drug Targets with Available Biological Structures 364Table 9: Number of Target-Target Interactions among Targets of Antibody Drugs in Cancer 369Table 10: Available Protein Expression Profiles of Antibody Drug Targets 372Table 11: Pathway Summary 383Table 12: Drug Targets without any Identified Assigned Pathways 383Table 13: Pathway Profiles According to BioCarta of Antibody Drug Targets in Oncology 386Table 14: Pathway Profiles According to KEGG of Antibody Drug Targets in Oncology 400Table 15: Pathway Profiles According to NetPath of Antibody Drug Targets in Oncology 418Table 16: Number of Drug Target Strategies by their Highest Developmental Stage and Uniqueness 423Table 17: Top Competitive Target Strategies of Antibody Drugs in Cancer 424Table 18: New and Unique Target Strategies of Antibody Drugs in Cancer in Pre-registration or on the Marketed 426Table 19: The Competition Through Close Mechanistic Approximation Between Antibody Drugs in Cancer Being Marketed 427Table 20: New and Unique Target Strategies in Phase III Clinical Development of Antibody Drugs in Cancer 428Table 21: The Competition Through Close Mechanistic Approximation Between Phase III Antibody Drugs in Cancer 429Table 22: New and Unique Target Strategies in Phase II Clinical Development of Antibody Drugs in Cancer 430Table 23: The Competition Through Close Mechanistic Approximation Between Phase II Antibody Drugs in Cancer 433Table 24: New and Unique Target Strategies in Phase I Clinical Development of Antibody Drugs in Cancer 435Table 25: The Competition Through Close Mechanistic Approximation Between Phase I Antibody Drugs in Cancer 439Table 26: New and Unique Target Strategies in Preclinical Development of Antibody Drugs in Cancer 442Table 27: The Competition Through Close Mechanistic Approximation Between Preclinical Antibody Drugs in Cancer 447Table 28: Target Strategies of Suspended or Terminated Antibody Drugs in Cancer 451Table 29: Connecting Target Strategy with Its Profile Identification Number 456Table 30: The Competition Through Close Mechanistic Approximation Among Antibody Drugs in Cancer 768Table 31 Competitive Summary by Cancer Indication of Antibody Drugs 778Table 32: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Acute Lymphocytic Leukemia 780Table 33: The Competition through Close Mechanistic Approximation between Acute Lymphocytic Leukemia Drugs 781Table 34: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Acute Myelogenous Leukemia 782Table 35: The Competition through Close Mechanistic Approximation between Acute Myelogenous Leukemia Drugs 783Table 36: Target Strategy Development Profiles of Antibody Drugs for the Treatment of B-cell Lymphoma 784Table 37: The Competition through Close Mechanistic Approximation between B-cell Lymphoma Drugs 785Table 38: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Basal Cell Cancer 786Table 39: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Biliary Cancer 787Table 40: The Competition through Close Mechanistic Approximation between Biliary Cancer Drugs 787Table 41: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Bladder Cancer 788Table 42: The Competition through Close Mechanistic Approximation between Bladder Cancer Drugs 788Table 43: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Bone Cancer 790Table 44: The Competition through Close Mechanistic Approximation between Bone Cancer Drugs 792Table 45: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Brain Cancer 793Table 46: The Competition through Close Mechanistic Approximation between Brain Cancer Drugs 794Table 47: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Breast Cancer 795Table 48: The Competition through Close Mechanistic Approximation between Breast Cancer Drugs 797Table 49: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Cancer (general) 799Table 50: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Carcinoid Tumors 800Table 51: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Cervical Cancer 801Table 52: The Competition through Close Mechanistic Approximation between Cervical Cancer Drugs 801Table 53: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Chronic Lymphocytic Leukemia 803Table 54: The Competition through Close Mechanistic Approximation between Chronic Lymphocytic Leukemia Drugs 804Table 55: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Chronic Myelogenous Leukemia 806Table 56: The Competition through Close Mechanistic Approximation between Chronic Myelogenous Leukemia Drugs 806Table 57: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Chronic Myelomonocytic Leukemia 807Table 58: Target Strategy Development Profiles of Antibody Drugs for the Treatment of CNS Cancer 808Table 59: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Colorectal Cancer 809Table 60: The Competition through Close Mechanistic Approximation between Colorectal Cancer Drugs 811Table 61: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Endometrial Cancer 813Table 62: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Esophageal Cancer 814Table 63: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Ewing's Sarcoma 815Table 64 The Competition through Close Mechanistic Approximation between Ewing's Sarcoma Drugs 815Table 65: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Fallopian Tube Cancer 816Table 66: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Gastrointestinal Cancer (general) 817Table 67: The Competition through Close Mechanistic Approximation between Gastrointestinal Cancer (general) Drugs 818Table 68: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Gastrointestinal Stomach Cancer 819Table 69: The Competition through Close Mechanistic Approximation between Gastrointestinal Stomach Cancer Drugs 820Table 70: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Gastrointestinal Stromal Cancer 821Table 71: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Genitourinary Cancer 822Table 72: The Competition through Close Mechanistic Approximation between Genitourinary Cancer Drugs 822Table 73: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Glioma 823Table 74: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Hairy Cell Leukemia 824Table 75: The Competition through Close Mechanistic Approximation between Hairy Cell Leukemia Drugs 824Table 76: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Head and Neck Cancer 825Table 77: The Competition through Close Mechanistic Approximation between Head and Neck Cancer Drugs 826Table 78: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Hematological Cancer (general) 827Table 79: The Competition through Close Mechanistic Approximation between Hematological Cancer Drugs 827Table 80: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Hodgkin's Lymphoma 828Table 81: The Competition through Close Mechanistic Approximation between Hodgkin's Lymphoma Drugs 829Table 82: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Leiomyo Sarcoma 830Table 83: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Leukemia (general) 831Table 84: The Competition through Close Mechanistic Approximation between Leukemia (general) Drugs 832Table 85: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Liver Cancer 833Table 86: The Competition through Close Mechanistic Approximation between Liver Cancer Drugs 834Table 87: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Lung Cancer (general) 835Table 88: The Competition through Close Mechanistic Approximation between Lung Cancer (general) Drugs 836Table 89: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Lymphoma (general) 837Table 90: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Malignant ascites 838Table 91: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Melanoma 839Table 92: The Competition through Close Mechanistic Approximation between Melanoma Drugs 840Table 93: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Merkel Cell Carcinoma 842Table 94: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Mesothelioma 843Table 95: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Myelodysplastic Syndrome 844Table 96: The Competition through Close Mechanistic Approximation between Myelodysplastic Syndrome Drugs 844Table 97: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Myeloma 846Table 98: The Competition through Close Mechanistic Approximation between Myeloma Drugs 847Table 99: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Nasopharyngeal Cancer 849Table 100: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Neuroblastoma 850Table 101: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Neuroectodermal Sarcoma 851Table 102: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Neuroendocrine Cancer (general) 852Table 103: Target Strategy Development Profiles of Antibody Drugs for the Treatment of non-Hodgkin's Lymphoma 853Table 104: The Competition through Close Mechanistic Approximation between non-Hodgkin's Lymphoma Drugs 855Table 105: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Non-Small Cell Lung Cancer 857Table 106: The Competition through Close Mechanistic Approximation between Non-Small Cell Lung Cancer Drugs 859Table 107: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Oesophageal Cancer 860Table 108: The Competition through Close Mechanistic Approximation between Oesophageal Cancer Drugs 862Table 109: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Oral Cancer 863Table 110: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Osteo Sarcoma 864Table 111: The Competition through Close Mechanistic Approximation between Osteo Sarcoma Drugs 864Table 112: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Ovarian Cancer 865Table 113: The Competition through Close Mechanistic Approximation between Ovarian Cancer Drugs 867Table 114: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Pancreatic Cancer 868Table 115: The Competition through Close Mechanistic Approximation between Pancreatic Cancer Drugs 870Table 116: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Peritoneal Cancer 871Table 117: The Competition through Close Mechanistic Approximation between Peritoneal Cancer Drugs 872Table 118: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Pituitary Adenoma 873Table 119: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Prostate Cancer 874Table 120: The Competition through Close Mechanistic Approximation between Prostate Cancer Drugs 876Table 121: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Renal Cancer 877Table 122: The Competition through Close Mechanistic Approximation between Renal Cancer Drugs 878Table 123: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Rhabdomyo Sarcoma 879Table 124: The Competition through Close Mechanistic Approximation between Rhabdomyo Sarcoma Drugs 879Table 125: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Sarcoma (general) 880Table 126: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Skin Appendage Cancer 881Table 127: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Skin Cancer (general) 882Table 128: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Small Cell Lung Cancer 883Table 129: The Competition through Close Mechanistic Approximation between Small Cell Lung Cancer Drugs 884Table 130: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Soft Tissue Sarcoma 885Table 131: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Solid Tumor 886Table 132: The Competition through Close Mechanistic Approximation between Solid Tumor Drugs 888Table 133: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Squamous Cell Cancer 890Table 134: The Competition through Close Mechanistic Approximation between Squamous Cell Cancer Drugs 890Table 135: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Synovial Sarcoma 892Table 136: Target Strategy Development Profiles of Antibody Drugs for the Treatment of T-cell Lymphoma 893Table 137: The Competition through Close Mechanistic Approximation between T-cell Lymphoma Drugs 893Table 138: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Testicular Cancer 894Table 139: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Thymoma Cancer 895Table 140: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Thyroid Cancer 896Table 141: The Competition through Close Mechanistic Approximation between Thyroid Cancer Drugs 896Table 142: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Unspecified Cancer Type 898Table 143: The Competition through Close Mechanistic Approximation between Unspecified Cancer Type Drugs 902Table 144: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Vaccine adjunct 905Table 145: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Waldenstrom's hypergammaglobulinemia 906Table 146: The Competition through Close Mechanistic Approximation between of Waldenstrom's hypergammaglobulinemia Drugs 906Table 147: Competitive Summary by Investigator of Antibody Drug Development in Cancer 908Table 148: Summary Table of Corporate Changes in the Competitive Landscape of Cacner Antibody Drug Development 913Table 149: The Worst Ranking and the Highest Populated Level for Each of the 15 Ranking Parameters 916Table 150: Example of a Competitive Fall-Out Table (Targeting TNFSF11 Modified) 922Table 151: A&G Pharmaceutical's Included Antibody Drugs in Oncology and Competitive Fall-Out 926Table 152: Abbott's Included Antibody Drugs in Oncology and Competitive Fall-Out 931Table 153: Abcam's Included Antibody Drugs in Oncology and Competitive Fall-Out 941Table 154: Abiogen's Included Antibody Drugs in Oncology and Competitive Fall-Out 949Table 155: Ablynx's Included Antibody Drugs in Oncology and Competitive Fall-Out 957Table 156: AC Immune's Included Antibody Drugs in Oncology and Competitive Fall-Out 961Table 157: Acceleron Pharma's Included Antibody Drugs in Oncology and Competitive Fall-Out 965Table 158: Access' Included Antibody Drugs in Oncology and Competitive Fall-Out 970Table 159: Actinium Pharmaceuticals' Included Antibody Drugs in Oncology and Competitive Fall-Out 976Table 160: Active Biotech's Included Antibody Drugs in Oncology and Competitive Fall-Out 981Table 161: Adherex's Included Antibody Drugs in Oncology and Competitive Fall-Out 985Table 162: Affibody's Included Antibody Drugs in Oncology and Competitive Fall-Out 991Table 163: Affimed Therapeutics' Included Antibody Drugs in Oncology and Competitive Fall-Out 999Table 164: Affitech's Included Antibody Drugs in Oncology and Competitive Fall-Out 1008Table 165: AGY Therapeutics' Included Antibody Drugs in Oncology and Competitive Fall-Out 1014Table 166: Aida Pharmaceuticals' Included Antibody Drugs in Oncology and Competitive Fall-Out 1019Table 167: Alder Biopharmaceuticals' Included Antibody Drugs in Oncology and Competitive Fall-Out 1025Table 168: Alethia Biotherapeutics' Included Antibody Drugs in Oncology and Competitive Fall-Out 1031Table 169: Alexion's Included Antibody Drugs in Oncology and Competitive Fall-Out 1035Table 170: Algeta's Included Antibody Drugs in Oncology and Competitive Fall-Out 1041Table 171: ALSP's Included Antibody Drugs in Oncology and Competitive Fall-Out 1049Table 172: Altor BioScience's Included Antibody Drugs in Oncology and Competitive Fall-Out 1054Table 173: Amgen's Included Antibody Drugs in Oncology and Competitive Fall-Out 1063Table 174: Amorfix Life Sciences' Included Antibody Drugs in Oncology and Competitive Fall-Out 1088Table 175: Antisoma's Included Antibody Drugs in Oncology and Competitive Fall-Out 1093Table 176: Aphios' Included Antibody Drugs in Oncology and Competitive Fall-Out 1099Table 177: Apricus Biosciences' Included Antibody Drugs in Oncology and Competitive Fall-Out 1106Table 178: Arana Therapeutics' Included Antibody Drugs in Oncology and Competitive Fall-Out 1112Table 179: Arca biopharma's Included Antibody Drugs in Oncology and Competitive Fall-Out 1116Table 180: Areva's Included Antibody Drugs in Oncology and Competitive Fall-Out 1122Table 181: arGEN-X's Included Antibody Drugs in Oncology and Competitive Fall-Out 1128Table 182: Astellas' Included Antibody Drugs in Oncology and Competitive Fall-Out 1132Table 183: AstraZe

To order this report:Pathology Industry: Cancer Antibodies: Drug Target Atlas and Competitive Outlook

Nicolas Bombourg

Reportlinker

Email: nicolasbombourg@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved


Related biology technology :

1. MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020
2. Virobays Spectrum-Selective Cathepsin Inhibitor Shows Efficacy in Bone Cancer Model
3. Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs)
4. NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer
5. Members of Congress, Cancer Experts Address Impact of Genetic Testing on Cancer
6. Masaryk Memorial Cancer Institute Reduces Losses and Administrative Overhead With Ekahau RTLS
7. BBVA Foundation Unites the Efforts of Massachusetts General Hospital and Barcelonas Vall dHebron Hospital in Biomarker Research for Personalized Cancer Therapies
8. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
9. New research points to benefits of innovative cobas® HPV test for primary screening as Englands cervical cancer screening programme includes the test in current HPV "triage" rollout
10. A New Type of Dendritic Cell-Based Cancer Vaccine has Received Approval for Clinical Tests and at the Same Time Secures Substantial Financing
11. US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... February 11, 2016 , ... ... new stem cell treatment clinic in Quito, Ecuador. The new facility will provide ... applications to patients from around the world. , The new GSCG clinic ...
(Date:2/10/2016)... ASAE is introducing a hybrid membership model ... the option of joining or renewing through an organizational ... staff size, every employee in any size association or ... all available member benefits.   John H. ... options will allow organizations of any size and their ...
(Date:2/10/2016)... ... 2016 , ... Benchmark Research, a fully-integrated network of ... principal investigators (PI) to the roles of Chief Medical Officer, Clinical Research and ... Chu, a Benchmark Research PI in the Austin office, will assume the role ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... now available on Microsoft Azure. On Azure, Arvados provides capabilities for managing and ... clear demand for Microsoft Azure from major institutions collecting and analyzing genomic data,” ...
Breaking Biology Technology:
(Date:2/9/2016)... 2016 Vigilant Solutions announces today that an agency ... develop a lead in a difficult homicide case. The agency ... locate the suspect vehicle. Due to the ongoing investigation, the ... omitted at the agency,s request. --> ... victim was found deceased at an intersection here in the ...
(Date:2/3/2016)... February 3, 2016 --> ... research report "Automated Fingerprint Identification System Market by Component ... Application (Banking & Finance, Government, Healthcare, and Transportation) and ... the market is expected to be worth USD 8.49 ... between 2015 and 2020. The transformation and technology evolution ...
(Date:2/2/2016)... , Feb. 2, 2016 Checkpoint Inhibitors ... Rising Market Are you interested in the ... revenues for checkpoint inhibitors. Visiongain,s report gives those ... product and national level. Avoid falling behind ... progress, opportunities and revenues those emerging cancer therapies ...
Breaking Biology News(10 mins):